<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151274">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01808989</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00001</org_study_id>
    <nct_id>NCT01808989</nct_id>
  </id_info>
  <brief_title>Clinical Interest of the TcPO2 Technique</brief_title>
  <acronym>CINEYSOFT</acronym>
  <official_title>Multicentric Study of the Clinical Interest of the TcPO2 Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The measurement of the transcutaneous oxygen pressure records simultaneously the tcpO2 at
      the buttocks and chest level during walking. On the first, this measurement shows a
      segmental ischemia effort with an index named DROP (at the buttocks level) and, on the other
      hand, abnormal oximetry.

      The present study focuses on the clinical interest of the transcutaneous oxygen pressure
      during exercise in the diagnosis of claudication in patient referred for an oximetry
      exercise test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre-test and post test diagnostic hypothesis with probablity will be completed by the
      physician  as a fonction of the test results.

      Pre-test and post test treatments ongoing or scheduled will be completed by the physician
      as a fonction of the test results.

      Analysis will be done on differences of pre and post test results.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The percentage of patients for whom results tcpO2 effort led to changes in diagnosis measured by the questionnaire filled by the doctor in charge of the patient before and after the test</measure>
    <time_frame>up to 1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>during a walk on a treadmill, there is a DROP of tcpo2&lt;-15</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Claudication</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with buttock pain and referred for an oximetry exercise test
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between 40 and 80 years old

          -  referred for an oximetry exercise test

          -  Patient able to walk on a treadmill

          -  Patient covered by the French health insurance

          -  Patient able to understand the protocol

          -  Patient agrees to be involve in the protocol and sign the consent form

        Exclusion Criteria:

          -  any heart issues during the last 3 months

          -  pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Abraham, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital , Angers, FRANCE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre ABRAHAM, MD; Ph.D</last_name>
    <phone>33-(0)-2-41-35-36-10</phone>
    <email>PiAbraham@chu-angers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle DURAND ZALESKI, MD; Ph.D</last_name>
    <phone>33-(0)-1-40-27-41-43</phone>
    <email>isabelle.durandzaleski@hmn.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre ABRAHAM, MD, Ph.D</last_name>
      <phone>33-(0)-2-41--35-36-10</phone>
      <email>PiAbraham@chu-angers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle DURAND ZALESKI, MD, Ph.D</last_name>
      <phone>33-(0)-40-27-41-43</phone>
      <email>isabelle.durandzaleski@hmn.aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre ABRAHAM, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle DURAND ZALESKI, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabrielle SARLON</last_name>
    </contact>
    <investigator>
      <last_name>Gabrielle SARLON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume MAHE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume MAHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Bura Riviere, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandra BURA RIVIERE, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Aubourg, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marion Aubourg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>March 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peripheral artery disease</keyword>
  <keyword>tcpo2</keyword>
  <keyword>treadmill walking test</keyword>
  <keyword>intermittent claudiaction</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
